Science

PROMISE Study

The ReSViNET Foundation and ReSViNET’s Patient Network are partners in IMI’s PROMISE study. The aim of PROMISE is to significantly advance our understanding of RSV to aid in the design of public health strategies as well as the development and use of vaccines and therapeutics in both children and older people. It builds on the work of IMI’s RESCEU project, which has delivered significant insights and resources on RSV.

PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brings together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world class organisations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Specifically, this initiative funded by the Innovative Medicines Initiative (IMI), focuses on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe. Since the development of preventative measures such as a vaccine and monoclonal antibodies are well under way, PROMISE aims to prepare for the introduction of such treatments and prophylactic interventions.

PROMISE is located in:
Belgium
Germany
Italy
The Netherlands
Spain
United Kingdom
Finland
France

Survey Study

As a Foundation, we aim to combat RSV (Respiratory Syncytial Virus) all around the world. Therefore, it is important for us to create more awareness of the disease that is caused by RSV. We have joined forces with Sanofi to set-up a survey study, to learn what parents need from organisations and health practitioners to be well informed about RSV. Moreover, we wanted to gain a better understanding of your opinion as a (soon to be) parent on vaccinating your child against RSV and what method of vaccinating you prefer. The study has been completed.

PROMISE case-control Study

The aim of the PROMISE case control study is to find out why some children with RSV-infection become more ill than others. For this reason, we look at certain biomarkers (proteins) in the body that might tell us something about the severity of disease. We collect blood, saliva, urine and faeces of previously healthy term born babies under the age of one. Hereby, we aim to gain more insight into the differences in biomarkers of children with severe RSV-infection, compared to children with less severe RSV-infection and healthy children. In the future, we hope this information enables us to determine which children are at high risk for severe infection with this virus. This PROMISE study is conducted in a European collaboration of academic hospitals and pharmaceutical companies, called the PROMISE consortium. Currently, only children in the Netherlands are included in the PROMISE case-control study.

PRIMA Study

‘’The PRIMA birth cohort aims to study which components in breastfeeding contribute to its protection of the infant against the development of respiratory tract infections and allergies in their first year of life. For this, we intend to follow 1000 healthy mother-child pears in Utrecht and surroundings, in the centre of the Netherlands. Along the way, several sub-studies and projects have been implemented within the cohort. We are also looking into the antibody-transfer via the placenta, amniotic fluid and breast milk in 5-15 mother-child pairs. Currently, a sub-study of 250 mother-child pairs is ongoing in which we additionally ask the mothers to fill in questionnaires about their diet. With this information, we can study the impact of the maternal diet on the breast milk composition and with that, on the protection the breast milk provides. For more information, please take a look at the website (Dutch only) or contact us via prima@umcutrecht.nl.’